The role of adjunctive exenatide therapy in pediatric type 1 diabetes

Vandana S. Raman, Kimberly J. Mason, Luisa M. Rodriguez, Krishnavathana Hassan, Xiaoying Yu, Lisa Bomgaars, Rubina A. Heptulla

Research output: Contribution to journalArticle

64 Scopus citations

Abstract

OBJECTIVE- Exenatide improves postprandial glycemic excursions in type 2 diabetes. Exenatide could benefit type 1 diabetes as well. We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS- Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide. Two doses of exenatide (1.25 and 2.5 μg) were compared with insulin monotherapy. Prandial insulin dose was reduced by 20%. Gastric emptying and hormones were analyzed for 300 min postmeal. RESULTS- Treatment with both doses of exenatide versus insulin monotherapy significantly reduced glucose excursions over 300 min (P < 0.0001). Exenatide administration failed to suppress glucagon but delayed gastric emptying (P < 0.004). CONCLUSIONS- Adjunctive exenatide therapy reduces postprandial hyperglycemia in adolescents with type 1 diabetes. This reduction in glucose excursion occurs despite reduction in insulin dose. We suggest that exenatide has therapeutic potential as adjunctive therapy in type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)1294-1296
Number of pages3
JournalDiabetes Care
Volume33
Issue number6
DOIs
StatePublished - Jun 2010
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Raman, V. S., Mason, K. J., Rodriguez, L. M., Hassan, K., Yu, X., Bomgaars, L., & Heptulla, R. A. (2010). The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care, 33(6), 1294-1296. https://doi.org/10.2337/dc09-1959